Ewan Pearson
Overview
Explore the profile of Ewan Pearson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Coley K, Wang Q, Packer R, John C, Abner E, Reis K, et al.
Nicotine Tob Res
. 2025 Jan;
PMID: 39792440
Introduction: Varenicline is an α4β2 nicotinic acetylcholine receptor partial agonist with the highest therapeutic efficacy of any pharmacological smoking cessation aid and a 12-month cessation rate of 26%. Genetic variation...
2.
Lin Y, Leith D, Abbott M, Barrett R, Bell S, Croudace T, et al.
BMJ Open
. 2024 Nov;
14(11):e086594.
PMID: 39613429
Introduction And Aim: Diabetes is a global health emergency with increasing prevalence and diabetes-associated morbidity and mortality. One of the challenges in optimising diabetes care is translating research advances in...
3.
Delfin C, Dragan I, Kuznetsov D, Tajes J, Smit F, Coral D, et al.
Life (Basel)
. 2024 Feb;
14(2).
PMID: 38398771
Obesity is considered by many as a lifestyle choice rather than a chronic progressive disease. The Innovative Medicines Initiative (IMI) SOPHIA (Stratification of Obesity Phenotypes to Optimize Future Obesity Therapy)...
4.
Cordiner R, Bedair K, Mari A, Pearson E
J Clin Endocrinol Metab
. 2024 Jan;
109(8):2106-2115.
PMID: 38267622
Context: Low-dose sulfonylureas (SUs) have been found to augment the classical incretin effect, increase glucose sensitivity and late phase incretin potentiation. Objective: To evaluate potential synergy between low-dose SU plus...
5.
Witham M, Granic A, Pearson E, Robinson S, Sayer A
Drugs Aging
. 2023 Jul;
40(8):703-719.
PMID: 37486575
Sarcopenia, the age-related loss of muscle strength and mass or quality, is a common condition with major adverse consequences. Although the pathophysiology is incompletely understood, there are common mechanisms between...
6.
Allesoe R, Lundgaard A, Hernandez Medina R, Aguayo-Orozco A, Johansen J, Nissen J, et al.
Nat Biotechnol
. 2023 May;
41(7):1026.
PMID: 37130959
No abstract available.
7.
Dalgard Dunvald A, Nielsen F, Olsen D, Ernst M, Donnelly L, Soto-Pedre E, et al.
Br J Clin Pharmacol
. 2023 Mar;
89(8):2529-2541.
PMID: 36967527
Aims: Drug metabolism might be altered in patients with type 2 diabetes. We aimed to evaluate if initiation of glucose-lowering drugs impacts warfarin efficacy and drug metabolism. Methods: First, we...
8.
Allesoe R, Lundgaard A, Hernandez Medina R, Aguayo-Orozco A, Johansen J, Nissen J, et al.
Nat Biotechnol
. 2023 Jan;
41(3):399-408.
PMID: 36593394
The application of multiple omics technologies in biomedical cohorts has the potential to reveal patient-level disease characteristics and individualized response to treatment. However, the scale and heterogeneous nature of multi-modal...
9.
Wesolowska-Andersen A, Brorsson C, Bizzotto R, Mari A, Tura A, Koivula R, et al.
Cell Rep Med
. 2022 Feb;
3(1):100477.
PMID: 35106505
The presentation and underlying pathophysiology of type 2 diabetes (T2D) is complex and heterogeneous. Recent studies attempted to stratify T2D into distinct subgroups using data-driven approaches, but their clinical utility...
10.
Reel P, Reel S, Pearson E, Trucco E, Jefferson E
Biotechnol Adv
. 2021 Apr;
49:107739.
PMID: 33794304
With the development of modern high-throughput omic measurement platforms, it has become essential for biomedical studies to undertake an integrative (combined) approach to fully utilise these data to gain insights...